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A Markov model, based on data from randomised trials, was
developed to compare the 5 alternative interventions: chlorthali-
done, propranolol, amlodipine, silazapril and losartan. A 
cost-effectiveness analysis was performed, based on numbers-
needed-to-treat (NNT) derived from a published metaanalysis.
The primary outcome measure was the NNT to prevent one fatal
cardiovascular disease event and the secondary outcome measure
was the NNT to prevent one stroke (fatal and nonfatal). Cost
data were derived from public sources. Only direct costs were
considered in the analysis. All costs were calculated from the per-
spective of the public insurance system organisations, in 2003
Euros. Future costs and clinical beneﬁts were discounted at 5%.
The time horizon was 5 years. Sensitivity analyses tested the
effect of modifying the input parameters on the economic end-
points. RESULTS: No signiﬁcant differences in efﬁcacy presented
among drug groups in mild to moderate hypertension. The NNT
for 5 years to prevent one fatal cardiovascular disease event 
was 135.27 patients and to prevent one stroke was just 
64.05 patients. The estimated total cost to prevent one fatal 
cardiovascular disease event was 78,121.40€, 84,040.63€,
118,825.36€, 103,098.82€, and 168,485.60€ for chlorthalidone,
propranolol, amlodipine, silazapril and losartan respectively. The
estimated total cost to prevent one stroke was 36,990.28€,
39,793.02€, 56,263.50€, 48,817.03€ and 79,777.50€ respec-
tively. Sensitivity analysis conﬁrmed the superiority of chlor-
thalidone against the other antihypertensive agents.
CONCLUSIONS: In mild to moderate hypertension, chlorthali-
done is more cost-effective than propranolol, amlodipine, silaza-
pril and losartan and should be considered as the ﬁrst choice of
antihypertensive therapy.
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OBJECTIVE: To asses the economic consequences of antihyper-
tensive treatment with perindopril and enalapril in the elderly,
from the third-party payer perspective. METHODS: The clini-
cal, epidemiological and economic data were derived from a sci-
entiﬁc project conducted among GPs’ in the whole of Poland,
and concerned 159 patients over 65. treated in mono-therapy
within the last year. Calculations were made from the third-party
payer perspective. The retrospective approach was applied. The
direct medical costs of: drug reimbursement, physicians’ consul-
tations, hospitalisation, laboratory and diagnostic tests were
identiﬁed and calculated. Effectiveness was measured by the 
percentage of the patients with appropriately controlled blood
pressure (BP < 140/90mmHg) in accordance with JNC VII guide-
lines. RESULTS: The measured effectiveness of the mono-
therapy was 43% in the perindopril group and 24% in the
enalapril group. Cost of the hospitalisation in the perindopril
group was 54.95% lower than in the enalapril group, which is
equivalent to 89.52€ saved per patient per year. Physicians’ con-
sultations cost reduction in the perindopril group amounted to
15.18€ (21.59%) per patient per year. There was no signiﬁcant
difference in the costs of laboratory and diagnostic tests between
the compared treatments (30.93€ and 27.28€ respectively).
Treatment with perindopril requires additional payer’s expendi-
ture of 18.95€ per patient per year. Total costs measured from
the third-party payer perspective in the perindopril group, were
30.08% lower than in the enalapril group which equalled 82.10€
saved per each patient per year. CONCLUSION: Taking third-
party payer perspective into consideration, mono-therapy with
perindopril is superior to treatment with enalapril in elderly
patients due to better blood pressure control and essential
savings resulting mainly from the reduction of both hospitalisa-
tion and physicians’ consultation costs.
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OBJECTIVE: The purpose of this study was to compare the costs
associated with the prescription of various initial monotherapies
for mild to moderate hypertension in Greece, when following
2003 European Society of Hypertension—European Society of
Cardiology guidelines. In these guidelines, it is concluded that
the 5 major classes of antihypertensive agents are suitable for the
initiation and maintenance of antihypertensive therapy because
of their similar protection against total and cardiovascular mor-
tality. METHODS: A cost-minimization analysis was performed,
based on numbers-needed-to-treat (NNT) derived from a pub-
lished metaanalysis. An economic model was developed to
compare the 5 alternative interventions: diuretics (chlorthali-
done), â-blockers (propranolol), calcium-channel blockers
(amlodipine), angiotensin-converting enzyme inhibitors (silaza-
pril) and angiotensin receptor blockers (losartan). Cost data were
derived from public sources. Only direct costs were considered
in the analysis including the cost of drug therapy, monitoring,
treating side-effects, poor compliance and switching. All costs
were calculated from a third-party payer perspective, in 2003
Euros. Future costs were discounted at 5%. The time horizon
was 5 years. RESULTS: The total cost to achieve and maintain
hypertension control was 666.21€, 716.69€, 1013.32€, 879.21€,
and 1436.82€ for chlorthalidone, propranolol, amlodipine,
silazapril and losartan respectively. The drug acquisition cost was
20.85%, 29.98%, 53.30%, 45.65%, and 68.22% respectively.
Drug acquisition cost and cost of laboratory monitoring were
more than 85% of the total treatment cost for all the antihy-
pertensive agents. Sensitivity analysis tested the effect of modi-
fying the prices of the antihypertensive agents and laboratory
monitoring, the doses of the alternative drugs and the compli-
ance rate on the economic endpoints and conﬁrmed the superi-
ority of chlorthalidone. CONCLUSIONS: In mild to moderate
hypertension, the 5 major classes of antihypertensive agents
provide similar protection against total and cardiovascular mor-
tality, but diuretics are cheaper than the others. Diuretics should
be considered as the ﬁrst choice of antihypertensive treatment.
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OBJECTIVES: Recent randomised studies have indicated that
Hormone Replacement Therapy (HRT) does not reduce the risk
of cardiovascular events neither in secondary nor in primary pre-
vention. Evidence of the effect of HRT on breast cancer has been
inconclusive, but now the general belief is that the risk of breast
cancer increases. In line with the results found in the Women’s
Health Initiative (WHI) the cost-effectiveness of HRT therapy,
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based on a societal perspective, was assessed for women with
menopausal symptoms. METHODS: An individual state transi-
tion model populated Swedish data was used to estimate the
cost-effectiveness of women with menopausal symptoms. The
model consists of the following disease states: Coronary Heart
Disease (CHD), Stroke, Venous thromboembolic events (VTE),
breast cancer, colorectal cancer, hip fracture, vertebral fracture
and wrist fracture. HRT therapy was modelled by its impact on
the disease risks during therapy and possible effects after the ces-
sation of therapy. The model calculates costs and health effects
or quality adjusted life years (QALYs) with and without inter-
vention. The resulting cost per gained QALY was compared to
the value of a gained QALY, which was set to 65,000€.
RESULTS: The cost per QALY gained for Swedish women with
intact uterus and menopausal symptoms were estimated to
1404€, 1188€, and 1004€ when the therapy started at the age of
50, 55, and 60, respectively. The cost per QALY gained was
found to be below the set value of a QALY at very low symptom
related reductions in the quality of life. CONCLUSIONS: The
results indicate that there is high probability that HRT is 
cost-effective for the treatment of women with menopausal
symptoms.
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OBJECTIVE: Stroke is a major cause of morbidity, health service
use, and death in the UK. Previous studies report substantial
associated costs, particularly related to hospitalisation. However,
no previous UK analysis has used data from a population-based
incidence study with full case ascertainment, without which
major inclusion bias is likely. Using data from such a study, we
estimate the acute costs per patient over the ﬁrst year from initial
stroke, by severity of stroke and prior atrial ﬁbrillation.
METHODS: Event and hospitalisation (inpatient or outpatient)
data were obtained from the Oxford Vascular Study, a prospec-
tive cohort study of all individuals in 9 general practices in
Oxfordshire, UK, which identiﬁed 346 patients experiencing a
stroke from April 1, 2002–March 31, 2004. Transient ischaemic
attacks were excluded. Mean costs per patient were calculated,
adjusting for censoring. RESULTS: In all, 212 (62%) patients
were admitted, the remainder being managed in the outpatient
clinic. The mean censoring-adjusted cost per patient was
GBP6508, 69% of which was incurred within 60 days after the
index event. Patients with stroke recurrence in the study period
incurred costs of £7881 compared to GBP6089 in those without.
Costs in patients with prior atrial ﬁbrillation were £9757, com-
pared with £5687 in those without (p = 0.028). Patient costs by
stroke severity (28-day Rankin score 0/1 = mild, 2/3 = moder-
ate, 4/5 = severe, 6 = dead) were £1138, £7471, £18181, and
£1602. CONCLUSIONS: We derived reliable and up-to-date
estimates of acute care costs associated with stroke over the ﬁrst
12 months, using data from an “ideal” population-based inci-
dence study. The impact of severity of initial stroke and of prior
atrial ﬁbrillation on subsequent costs. Our estimates, which will
be extended as follow-up continues, should be of value to ana-
lysts interested in assessing the burden of stroke and the cost-
effectiveness of interventions.
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OBJECTIVES: Beta-blockers have provided evidence of improv-
ing survival in chronic heart failure (CHF) patients. Speciﬁcally,
the Cardiac Insufﬁciency Bisoprolol Study II (CIBIS-II) has
demonstrated a signiﬁcant reduction in mortality and morbidity
among patients with moderate to severe CHF treated with biso-
prolol. Our aim was to investigate the economic consequence of
bisoprolol therapy in CHF patients in Italy. METHODS: Data
were derived from the CIBIS-II trial. We conducted a cost-
effectiveness analysis, comparing standard care + bisoprolol vs
standard care + placebo in the perspective of the Italian National
Health Service (NHS). We identiﬁed and quantiﬁed medical
costs: drug costs according to the Italian market price; specialist
visits for initiation and up-titration of bisoprolol therapy and
hospitalizations were quantiﬁed on the basis of the NHS tariffs
(2004). Effects were measured in terms of mortality and mor-
bidity reduction (number of deaths, life years saved and fre-
quency of hospitalizations). We considered an observational
period of 1.3 years that was the average follow-up recorded in
the trial. Discounting was not performed because of the relatively
short follow-up of patients. We conducted one-way sensitivity
analyses on unit cost and effectiveness. RESULTS: The overall
cost of care per 1000 patients treated for 1.3 years was estimated
in 2,043,700€ in the bisoprolol group and in 2,366,168€ in the
placebo group, resulting in a net saving of 322,468€. The
number of additional patients alive with bisoprolol was 55 per
1000 patients, the number of LYS was 36 at 1.3 year. CON-
CLUSION: Bisoprolol therapy is dominant since it is both less
costly and more effective than standard care. Results of sensi-
tivity analysis showed that bisoprolol therapy remains dominant
even to changes in unit cost of drug, hospitalizations and fre-
quency of hospital admissions.
PCV25
SMOKING CESSATION FOR PRIMARY PREVENTION OF
CARDIOVASCULAR DISEASE:A COST-EFFECTIVENESS
ANALYSIS
Der Kinderen AJ, Franco OH, De Laet C
Department of Public Health, Erasmus MC, University Medical
Center Rotterdam, Rotterdam,The Netherlands
OBJECTIVES: The effectiveness of smoking cessation (SC) in the
reduction of cardiovascular disease (CVD) risk is demonstrated.
However, different options exist with variable levels of costs and
effects and which one to choose for primary prevention of CVD
is unclear. We evaluated the cost-effectiveness of different strate-
gies of SC. METHODS: Using data from the Framingham Heart
Study and the Framingham Offspring Study we built multistate
life tables to model the cost-effectiveness of different SC thera-
pies (Nurse or GP advice, nicotine substitutes (with or without
GP guidance), buproprion and a combination of buproprion and
nicotine substitutes) in male smokers free of CVD at baseline and
aged between 45 and 65. Participants were categorized in terms
of 10 years absolute risk of coronary heart disease (based on the
Anderson Formulae) and age. Cessation rates, risk reduction
rates for CVD and relapse rates were taken from the literature.
We calculated the cost-effectiveness in terms of costs per year of
life saved (LYS) using a time horizon of 5 and 10 years. A third-
party payer perspective was used and cost and effects were dis-
counted at 4%. Costs were estimated either by tariffs or market
prices and costs of prevented events were taken from the litera-
ture. Finally, we compared the strategies in an (incremental) cost-
effectiveness analysis. RESULTS: Costs per LYS for all strategies
were negative at all levels of risk and age groups. SC with GP
advice was most favourable, ranging from -4919€ to -3187€
and SC with buproprion the least (-3460€, -1215€). In the in-
cremental analysis SC with nicotine substitutes alone is to be 
